Federal Circuit Appeals
Viewpoints
Filter by:
Supreme Court Upholds Brulotte Rule Prohibiting Post-Expiration Patent Royalties
June 23, 2015 | Alert | By Bruce Sokler, Sandra Badin, Rich Gervase
On June 22, 2015, the Supreme Court issued its decision in Kimble v. Marvel Entertainment, LLC, upholding the rule, first announced in Brulotte v. Thys Co., 379 U. S. 29 (1964), that an agreement allowing a patent owner to collect royalty payments after a patent’s expiration is unlawful per se.
Read more
Second Circuit Holds a Hard Switch Between Drugs Is an Unlawful Product Hop Under Section 2
June 4, 2015 | Alert | By Bruce Sokler
On May 22, 2015, in a much-watched case, the Second Circuit upheld a preliminary injunction against Actavis PLC and its wholly owned subsidiary, Forest Laboratories, LLC (collectively “Actavis” or “Forest”), finding that Actavis’s “hard switch” strategy to launch an extended-release version of its blockbuster Alzheimer’s therapy and delist the immediate-release version would likely violate Section 2 of the Sherman Act.
Read more
Explore Other Viewpoints:
- Data Centers & Digital Infrastructure
- AI: The Washington Report
- Antitrust and Federal Regulation
- Appellate
- Arbitration, Mediation & Alternate Dispute Resolution
- Artificial Intelligence
- Awards
- Bankruptcy & Restructuring
- California Land Use
- Cannabis
- Class Action
- Complex Commercial Litigation
- Construction
- Consumer Product Safety
- Consumer Protection Defense
- Corporate Governance (ESG)
- Crisis Management and Strategic Response
- Cross-Border Asset Recovery
- DEI Legal Developments
- Debt Financing
- Direct Investing (M&A)
- Diversity
- EB-5 Financing
- Education & Nonprofits
- Employment
- EnforceMintz
- Environmental (ESG)
- Environmental Enforcement Defense
- Environmental Law
- Environmental, Social, and Corporate Governance (ESG)
- FDA Regulatory
- FDA in Flux
- False Claims Act
- Federal Circuit Appeals
- Financial Institution Litigation
- Government Law
- Growth Equity
- Health Care
- Health Care Compliance, Fraud and Abuse, & Regulatory Counseling
- Health Care Enforcement & Investigations
- Health Care Transactions
- Health Information Privacy & Security
- IP Due Diligence
- IPRs & Other Post Grant Proceedings
- Immigration
- Impacts of a New US Administration
- Insolvency & Creditor Rights Litigation
- Institutional Investor Class Action Recovery
- Insurance & Financial Services
- Insurance Consulting & Risk Management
- Insurance and Reinsurance Problem-Solving & Dispute Resolution
- Intellectual Property
- Investment Funds
- Israel
- Licensing & Technology Transactions
- Life Sciences
- Litigation & Investigations
- M&A Litigation
- ML Strategies
- Managed Care
- Medicare, Medicaid and Commercial Coverage & Reimbursement
- Mergers & Acquisitions
- Patent Litigation
- Patent Prosecution & Strategic Counseling
- Pharmacy Benefits and PBM Contracting
- Portfolio Companies
- Privacy & Cybersecurity
- Private Client
- Private Equity
- Pro Bono
- Probate & Fiduciary Litigation
- Products Liability & Complex Tort
- Projects & Infrastructure
- Public Finance
- Real Estate Litigation
- Real Estate Litigation, Construction & Infrastructure
- Real Estate Transactions
- Retail & Consumer Products
- Securities & Capital Markets
- Securities Litigation
- Social (ESG)
- Special Purpose Acquisition Company (SPACs)
- Sports & Entertainment
- State Attorneys General
- Strategic IP Monetization & Licensing
- Sustainable Energy & Infrastructure
- Tax
- Technology
- Technology, Communications & Media
- Technology, Communications & Media Litigation
- Trade Secrets
- Trademark & Copyright
- Trademark Litigation
- Unified Patent Court (UPC)
- Value-Based Care
- Venture Capital & Emerging Companies
- White Collar Defense & Government Investigations
- Women's Health and Technology